Erasca (ERAS) news
Recent news
Erasca shares jump to session high, up over 8%
AInvest Wire · 5d agoErasca, Inc.: Morgan Stanley raises target price to $21.00 from $12.00
Morgan Stanley has revised its price target for Erasca, Inc. (ERAS.US), raising it to $21.00 from $12.00, while maintaining its "Hold" rating for the stock. The adjustment reflects the firm’s updated assessment of the company’s financial outlook and market positioning. Investors are advised to…
AInvest Wire · Jul 20, 2026Erasca Inc: Piper Sandler raises target price to $22 from $18
AInvest Wire · Jul 14, 2026Erasca announces pricing of upsized public offering of common stock
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, has announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share, generating expected gross proceeds of $225.0…
AInvest Wire · Jul 14, 2026Ersca shares down 3.5% after the bell; announces proposed public offering of $500 mln of common stock
Erasca, Inc. (NASDAQ: ERAS) shares declined 3.5% in after-hours trading following the company’s announcement of a proposed public offering of $500 million in common stock. The clinical-stage precision oncology company plans to sell shares in an underwritten offering, subject to market and other…
AInvest Wire · Jul 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.